Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects

Trial Profile

A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2018

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Anxiety disorders; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 26 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 26 Mar 2018 Planned End Date changed from 9 Sep 2018 to 5 Apr 2018.
    • 26 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top